Sponsored

Chimeric Therapeutics (ASX: CHM) shares welcome additional positive preclinical data for CHM 1301 - Kalkine Media

November 28, 2023 11:30 AM AEDT | By Team Kalkine Media
Follow us on Google News: https://kalkinemedia.com/resources/assets/public/images/google-news.webp

Highlights

  • Chimeric is advancing CHM 1301 program to the next stage of preclinical development.
  • CHM 1301 is a next generation chlorotoxin (CLTX) chimeric antigen receptor (CAR) NK cell therapy.
  • The therapy demonstrated highly promising efficacy in preclinical studies of in vitro models of human ovarian cancer and pancreatic cancer.
  • CHM shares charged higher by 7%.

Chimeric Therapeutics Limited (ASX: CHM) shares gained over 7% on 28 November 2023 as the company announced additional information on its earlier update focused on positive in vitro data for CHM 1301.

The next generation CLTX CAR NK cell therapy program is entering the next phase of preclinical development. Under the study, the company plans to use armoured NK cell platform (CHM 0301) that was recently developed.

The study would aim to boost cell potency and resistance against the immunosuppressive solid tumour microenvironment.

In-depth details

CHM 1301 is a combination of the efficacy of CHM 1101 and off-the-shelf convenience of CHM 02012, reflecting the synergies of assets in the Chimeric portfolio.

It was tested in preclinical in vitro models of human ovarian cancer and pancreatic cancer, delivering extremely promising efficacy, as per the company.

In ovarian cancer, cell killing rose up to 260% versus first generation CHM 0201 cells. In pancreatic cancer, cell killing surged up to 300% as against the first generation CHM 0201 cells.

The entry into these new disease areas shows the potential of CLTX CAR therapies of the company against additional high-unmet need solid tumour types beyond glioblastoma.

Now CHM is progressing the CHM 1301 program to the next stage of preclinical development by use of its NK cell platform, to increase cell potency as well as resistance against the immunosuppressive solid tumor microenvironment.

CHM shares traded at AU$0.030 on 28 November 2023.


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.

5 ASX Companies Leveraging AI to Drive Growth in 2024



We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.